Project Grant R01CA286609
Award Date
9/13/24
Completion Date
8/31/29
Dollars Obligated
$610K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This federal Project Grant award of $399,669.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research program) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for the treatment of glioblastoma (GBM), the most common and deadly primary brain cancer. The key products/services to be delivered under this award include: Developing a platform to generate potent and personalized GBM-specific T cells in an...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $420,251 to Brigham & Women's Hospital Inc. to develop an oncolytic virus therapy combined with engineered stem cells and immunomodulators for treating glioblastoma, the most lethal primary brain tumor. The key products and services to be delivered under this...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $163,640 to the Rector & Visitors of the University of Virginia to develop novel gene delivery platforms for the treatment of glioblastoma, an aggressive brain tumor. The project aims to engineer "brain-penetrating nanoparticles" (BPNs) that can more effectively deliver therapeutic genes to glioblastoma tumors, using focused ultrasound to enhance delivery across...
This Project Grant award, funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports the development of novel cellular therapies for the treatment of glioblastoma (GBM), a highly aggressive form of brain cancer. The $417,858 award, effective from January 7, 2025 through December 31, 2029, will enable researchers at Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to engineer mesenchymal stem cells (MSCs) to release...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,200,000 to Creative Biotherapeutics LLC to develop a novel biologic therapy for eradicating brain cancer and brain metastases. The award period runs from September 1, 2024 through August 31, 2025. The funded research aims to address the high mortality rates and lack of effective treatments for brain cancers, both primary and metastatic. Creative Biotherapeutics has discovered that...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research Program (CFDA 93.395), provides $1,881,613 in funding to The General Hospital Corporation (Massachusetts General Hospital) to develop and evaluate new oncolytic virus-based immunotherapies for glioblastoma, a deadly brain cancer. The key objectives are to create oncolytic herpes simplex viruses (OHSVs) that can stimulate the immune system and inhibit the immunosuppressive adenosine pathway...
The National Cancer Institute (NCI) awarded a $634,743 Project Grant under the Cancer Treatment Research Program (CFDA 93.395) to the University of California, Davis to develop novel nanotherapeutics to overcome therapy resistance in high-grade gliomas (HGGs), including glioblastoma (GBM). The project aims to 1) develop a series of potent bisaminoquinoline derivative (BAQD) loaded nanoparticles (BTN@BAQD) to inhibit autophagy and reverse drug resistance in HGGs, 2) evaluate their delivery and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a Phase I clinical trial testing a novel chimeric antigen receptor (CAR) T-cell therapy for the treatment of glioblastoma, a deadly brain cancer. The grant, totaling $652,725.00 and running from September 19, 2024 through August 31, 2029, supports the development and...
This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $451,996.00 to the University of Texas at Arlington (UTA) to develop an ex vivo high-throughput screening platform for identifying novel therapies targeting treatment-resistant glioblastoma (GBM) cells. The key products and services to be delivered under this grant include: Establishing an integrated high-throughput platform to quantitatively analyze the cellular/molecular...